Treatment with AC Pulsed Electromagnetic Fields Improves Olfactory Function in Parkinson's Disease

References

• Argiolas A., Melis M. R. The neuropharmacology of yawning. European Journal of Pharmacology 1998; 343: 1–16
   PubMed Web of Science ®Google Scholar
• Baenninger R., Binkley S., Baenninger M. Field observations of yawning and activity in humans. Physiology and Behavior 1996; 59: 421–425
   PubMedGoogle Scholar
• Blackman C. F., Benane S. G., House D. E., Elliott D. J. Importance of alignment between local DC magnetic field and an oscillating magnetic field in responses of brain tissue in vitro and in vivo. Bioelectromagnetics 1990; 11: 159–167
   PubMed Web of Science ®Google Scholar
• Blin O., Masson G., Azulay J. P., Fondarai J., Serratrice G. Apomorphine-indued blinking and yawning in healthy volunteers. British Journal of Clinical Pharmacology 1990; 30: 769–773
   PubMedGoogle Scholar
• Blin O., Azulay J. P., Masson G., Serratrice G. Yawning. Physiopathology and neuropharmacology. Therupie 1991; 46: 37–43
   PubMedGoogle Scholar
• Charuchinda C., Supavilai P., Karobath M., Palacios J. M. Dopamine D2 receptors in the rat brain: autoradiographic visualization using a high-affinity selective agonist ligand. Journal of Neuroscience 1987; 7: 1352–1360
   PubMedGoogle Scholar
• Coronas V., Srivastavd L. K., Liang J. J., Jourdan F., Moyse E. Identification and localization of dopamine receptor subtypes in rat olfactory mucosa and bulb: a combined in situ hybridization and ligand binding radioautographic approach. Journal of Chemical Neuroanatomy 1997; 12: 243–257
   PubMedGoogle Scholar
• Doty R. L., Deems D. A., Stellar S. Olfactory dysfunction in Parkinsonism: a general deficit unrelated Oqto neurologic signs, disease stage or disease duration. Neurology 1988; 38: 1237–1244
   PubMed Web of Science ®Google Scholar
• Doty R. L., Riklan M., Deems D. A., Reynolds C., Stellar S. The olfactory and cognitive deficits of Parkinson's disease: evidence for independence. Annals of Neurology 1989; 25: 166–171
   PubMedGoogle Scholar
• Doty R. L., Stern M. B., Pfeiffer C., Gollomp S. M., Hurtig H. I. Bilateral olfactory dysfunction in early stage treated and untreated idiopathic Parkinson's disease. Journal of Neurology Neurosurgery and Psychiatry 1991a; 55: 138–142
   Google Scholar
• Doty K. L., Singh A., Tetrud J., Langston J. W. Lack of major olfactory dysfunction in MPTP-induced Parkinsonism. Annals of Neurology 1992b; 32: 97–100
   PubMed Web of Science ®Google Scholar
• Doty R. L., Bromley S. M., Stern M. B. Olfactory testing as an aid in the diagnosis of Parkinson's disease: development of optimal discrimination criteria. Neurodegeneration 1995; 4: 93–97
   PubMedGoogle Scholar
• Dubocovich M. L., Hensler J. G. Modulation of 3H-dopamine released by different frequencies of stimulation from rabbit retina. British Journal of Pharmacology 1986; 88: 51–61
   PubMedGoogle Scholar
• Goren J. L., Friedman J. H. Yawning as an aura for an L-dopa-induced ‘on’ in Parkinson's disease. Neurology 1998; 50: 823
   PubMedGoogle Scholar
• Guthrie K. M., Pullara J. M., Marshall J. F., Leon M. Olfactory deprivation increases dopamine D2 receptor density in the rat olfactory bulb. Synapse 1991; 8: 61–70
   PubMedGoogle Scholar
• Halasz K., Ljungdahl A., Hokfelt T., Johansson O., Goldstein M., Park D., Biberfeld P. Transmitter histochemistry of the rat olfactory bulb: I. immunohistochemical localization of monoamine synthesizing enzymes. Support for intrabulbar, periglomerular dopamine neurons. Brain Research 1977; 126: 455–474
   PubMedGoogle Scholar
• Hawkes C. H., Shephard B. C., Daniel S. E. Olfactory dysfunction in Parkinson's disease. Journal of Neurology Neurosurgery and Psychiatry 1997; 62: 436–446
   PubMed Web of Science ®Google Scholar
• Hoehn M. M., Yahr M. D. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427–442
   PubMed Web of Science ®Google Scholar
• Kato T., Otsu Y., Furune Y., Yamamoto T. Different effects of L-, N- and T-type calcium channel blockers on striatal dopamine release measured by microdialysis in freely moving rats. Neurochemistry International 1992; 21: 99–107
   PubMedGoogle Scholar
• Kavaliers M., Ossenkopp K. P. Calcium channel involvement in magnetic field inhibition of morphie-induced analgesia. Naunyn Schmiedeberg Archives of Pharmacology 1987; 336: 308–315
   Google Scholar
• Korten J. J., Meulstee J. Olfactory disturbances in Parkinsonism. Clinical Neurology and Neurosurgery 1980; 82: 113–118
   PubMedGoogle Scholar
• Lal S., Grassino A., Thavundayil J. X., Dubrovsky B. A simple method for the study of yawning in man induced by the dopamine receptor agonist apomorphine. Progress in Neuropsychopharmacology and Biological Psychiatry 1987; 11: 223–228
   PubMedGoogle Scholar
• Leitgeb N. Cyclotron resonance as a cause of biological effects of weak electric and magnetic fields. Biomedizinische Technologie 1990; 35: 135–138
   PubMedGoogle Scholar
• Matsumoto S., Yamada K., Nagashima M., Matsuo N., Shirakawa K., Furukawa T. Potentiation by serotonergic inhibition of yawning induced by dopamine receptor agonists in rats. Pharmacology Biochemistry and Behavior 1989; 32: 815–818
   PubMedGoogle Scholar
• Mogilnicka E., Kilmek V. Drugs affecting dopamine neurones and yawning behaviour. Pharmacology Biochemistry and Behavior 1977; 7: 303–305
   PubMed Web of Science ®Google Scholar
• Murofushi T, Mizuno M., Osanai R., Hayashida T. Olfactory dysfunction in Parkinson's disease. Journal of Otolaryngology and Relates Specialities 1991; 53: 143–146
   PubMedGoogle Scholar
• Nickell W. T., Norman A. B., Wyatt L. M., Shipley M. T. Olfactory bulb DA receptors may be located on terminals of the olfactory nerve Neuro Report 1991; 9–12
   Google Scholar
• Pearce R K., Hawkes C. H., Daniel S. F. The anterior olfactory nucleus in Parkinson's disease. Movement Disorders 1995; 10: 283–287
   PubMed Web of Science ®Google Scholar
• Philpot R D., Men D., McCarty R., Brunjes P. C. Activity dependent regulation of dopamine content in the olfactory bulbs of naris-occludcd rats. Neuroscience 1998; 85: 969–977
   PubMedGoogle Scholar
• Quinn N. P., Rossor M. N., Marsden C. D. Olfactory threshold in Parkinson's disease. Journal of Neurology Neurosurgery and Psychiatry 1987; 50: 88–89
   PubMed Web of Science ®Google Scholar
• Rollinson R. D., Wiggins W. S., Gilligan R. S. Drug-induced yawing successfully treated with pimozide. Archives of Neurology 1979; 36: 253
   Google Scholar
• Roth J., Radil T., Ruzicka E., Jech R, Tichy J. Apomorphine does not influence olfactory threshold in Parkinson's disease. Functional Neurology 1998; 13: 99–103
   PubMedGoogle Scholar
• Sandyk R. Weak magnetic fields in the treatment of Parkinson's disease with the ‘on-off’ phenomenon. International Journal of Neuroscience 1992; 66: 97–106
   PubMed Web of Science ®Google Scholar
• Smith S. D., McLeod B. R., Liboff A. R., Cooksey K. Calcium cyclotron resonance and diatom mobility. Bioelectromagnetics 1987; 8: 215–227
   PubMed Web of Science ®Google Scholar
• Serra G., Collu M., Gessa G. L. Dopamine receptors mediating yawning: are they autoreceptors. European Journal of Pharmacology 1986; 120: 187–192
   PubMed Web of Science ®Google Scholar
• Serra G., Collu M., Gessa G. L. Yawning is elicited by D2 dopamine agonists but is blocked by the D1 antagonist, SCH 23390. Psychopharmacology 1987; 91: 330–333
   PubMed Web of Science ®Google Scholar
• Szechtman H. Timing of yawns induced a small dose of apomorphine and its alteration by naloxone. Progress in Neuropsychopharmacology and Biological Psychiatry 1984; 8: 743–746
   PubMedGoogle Scholar
• Ward C. D., Hess W. A., Calne D. B. Olfactory impairment in Parkinson's disease. Neurology 1983; 33: 943–946
   PubMed Web of Science ®Google Scholar
• Watanabe Y., Lawlor G. F., Fujiwara M. Role of nerve terminal L-type Ca2+ channel in the brain. Life Sciences 1998; 62: 1671–1675
   PubMedGoogle Scholar
• Wenning G. K., Shephard B., Hawkes C., Petruckevitch A., Lees A., Quinn N. Olfactory function in atypical Parkinsonian syndromes. Acta Neurologica Scandinavica 1995; 91: 247–250
   PubMed Web of Science ®Google Scholar
• Yamada K., Tanaka M., Shibata K., Furukawa T. Involvement of septal and striatal dopamine D-2 receptors in yawning behavior in rats. Psychopharmacology 1986; 90: 9–13
   PubMed Web of Science ®Google Scholar
• Zarrindast M. R., Toloui V., Hashemi B. Erect of GABA-ergic drugs on physostigmine-induced yawning in rats. Psychoparmacology (Berlin) 1995a; 122: 297–300
   PubMedGoogle Scholar
• Zarrindast M. R., Fatehi F., Mohagheghi-Badi M. Effects of adenosine agents on apomorphine-induced yawning in rats. Psychopharmacology 1995b; 122: 292–296
   PubMedGoogle Scholar